AxoGen ( (AXGN) ) just unveiled an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Axogen, Inc., a leader in peripheral nerve repair solutions, reported a notable 17.9% revenue increase for Q3 2024 at $48.6 million, alongside a decrease in net loss to $1.9 million from $4.1 million in the previous year. The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high end of its revenue and gross margin guidance while maintaining its commitment to improving nerve repair standards globally.
Find detailed analytics on AXGN stock on TipRanks’ Stock Analysis page.
